Australia’s Healius on Tuesday said private equity firm Partners had offered to acquire the medical center operator for A$2.12 billion ($1.40 billion).
The Swiss private equity firm offered A$3.40 per share in cash, a 23.2% premium to Healius’ last closing price.
A filing earlier in the day showed Partners bought out China’s Jangh’s 15.9% majority stake in Healius.
Jangho had previously offered to buyout Healius for A$1.7 billion or A$3.25 per share, which was rejected by the Sydney-based company, saying it was “opportunistic” and fundamentally undervalued the company.
The company said it has not yet formed a view on Partners’ offer, adding that it was also subject to six weeks of due diligence.
Full Content: Reuters
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
UK Probes Lindab’s Acquisition of HAS-Vent Amid Fears of Market Monopoly
Apr 28, 2024 by
CPI
Shein Faces EU Regulations Over User Data
Apr 28, 2024 by
CPI
Google Fights Back Against US Antitrust Lawsuit
Apr 28, 2024 by
CPI
US Homeland Security Establishes Blue-Ribbon Board with Tech CEOs to Advise on AI
Apr 28, 2024 by
CPI
FTC Accuses Amazon Executives of Using Disappearing Messaging Apps to Conceal Evidence
Apr 28, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI